COVID-19 Records

Attachment

Gates Package, p.247 · gates:exh:00140

Page text: p.247 · original PDF

Date
(unknown precision)
Type
attachment · document
Topics
Gates Foundation involvementTherapeutics and treatmentsVaccines
Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Senior Vice President and Head, Immunology, Cardiovascular, Fibrosis and Global Health Thematic Research Center Bristol Myers Squibb Andrew Plump, M.D., Ph.D. President, Research & Development Takeda Pharmaceutical Co. Ltd. Mike Poole, M.D., FACP Therapeutic Accelerator Lead Bill & Melinda Gates Foundation Rachel Ramoni, D.M.D., Sc.D. Chief Research and Development Officer Department of Veterans Affairs Guido Rasi, M.D. Executive Director European Medicines Agency Sarah Read, M.D. Deputy Director, Division of AIDS National Institute of Allergy and Infectious Diseases, NIH John Reed, M.D., Ph.D. Executive Vice President, Global Head of Research & Development Sanofi David Reese, M.D. Executive Vice President, Research and Development Amgen Doris Rouse, Ph.D. Vice President, Global Health Technologies RTI Dan Skovronsky, M.D., Ph.D. Senior Vice President and Chief Scientific Officer Eli Lilly and Company Peter Stein, M.D. Director of Office of New Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration Paul Stoffels, M.D. Vice Chairman of the Executive Committee and Chief Scientific Officer Johnson & Johnson